Article
Common Patient Concerns about the Use of Glucagon-Like Peptide-1 Receptor Agonists in Diabetes Mellitus Management
Journal of the American Osteopathic Association
Document Type
Article
Publication Date
1-1-2012
Disciplines
Abstract
The authors present a case of a 46-year-old woman with type 2 diabetes mellitus who has been on a treatment regimen involving diet, exercise, and metformin. After 2 years of treatment, she has a body mass index of 35 and a glycosylated hemoglobin level of 8.0%, and this level is increasing. Her physician recommends adding a glucagon-like peptide-1 (GLP-1) receptor agonist to her treatment regimen, prompting her to ask several questions. The authors present these questions along with proposed answers, highlighting the practical application of GLP-1 receptor agonists in the context of common patient concerns.
PubMed ID
22267301
Citation Information
Jeffrey S. Freeman, James R. Gavin and Craig W. Spellman. "Common Patient Concerns about the Use of Glucagon-Like Peptide-1 Receptor Agonists in Diabetes Mellitus Management" Journal of the American Osteopathic Association Vol. 112 Iss. 1 Supplement 1 (2012) p. S22 - S24 Available at: http://works.bepress.com/jeffrey_freeman/8/
This article was published in Journal of the American Osteopathic Association, Volume 112, Issue 1, Supplement 1, January 2012, Pages S22-S24.
The published version is available at http://www.jaoa.org/content/112/1_suppl_1/S22.long
Copyright © 2012 by the American Osteopathic Association